Semiautomatic Tumor Delineation for Evaluation of 64Cu-DOTATATE PET/CT in Patients with Neuroendocrine Neoplasms: Prognostication Based on Lowest Lesion Uptake and Total Tumor Volume
- PMID: 33637589
- PMCID: PMC8612344
- DOI: 10.2967/jnumed.120.258392
Semiautomatic Tumor Delineation for Evaluation of 64Cu-DOTATATE PET/CT in Patients with Neuroendocrine Neoplasms: Prognostication Based on Lowest Lesion Uptake and Total Tumor Volume
Abstract
Patients with neuroendocrine neoplasms (NENs) have heterogeneous somatostatin receptor expression, with highly differentiated lesions having higher expression. Receptor expression of the total tumor burden may be visualized by somatostatin receptor imaging, such as with 64Cu-DOTATATE PET/CT. Assessment of maximal lesion uptake is associated with progression-free survival (PFS) but not overall survival (OS). We hypothesized that the lesion with the lowest, rather than the highest, 64Cu-DOTATATE uptake would be more prognostic, and we developed a semiautomatic method for evaluating this hypothesis. Methods: Patients with NENs underwent 64Cu-DOTATATE PET/CT. A standardized semiautomatic tumor delineation method was developed and used to identify the lesion with the lowest uptake, that is, with the lowest SUVmean Additionally, we assessed total tumor volume derived from the semiautomatic tumor delineation. Kaplan-Meier and Cox regression analyses were used to determine whether there was any association with OS and PFS. Results: In 116 patients with NENs, median PFS (95% CI) was 23 mo (range, 20-31 mo) and median OS was 85 mo (range, 68-113 mo). Minimum SUVmean and total tumor volume were significantly associated with PFS and OS in univariate Cox regression analyses, whereas SUVmax was significant only for PFS. In multivariate Cox analyses, both minimum SUVmean and total tumor volume remained statistically significant. Minimum SUVmean and total tumor volume were then dichotomized by their median, and patients were categorized into 4 groups: high or low total tumor volume and high or low minimum SUVmean Patients with a low total tumor volume and high minimum SUVmean had a hazard ratio of 0.32 (95% CI, 0.20-0.51) for PFS and 0.24 (95% CI, 0.13-0.43) for OS, both with P values of less than 0.001 (reference: high total tumor volume and low minimum SUVmean). Conclusion: We propose a standardized semiautomatic tumor delineation method to identify the lesion with the lowest 64Cu-DOTATATE uptake and total tumor volume. Assessment of the lowest, rather than the highest, lesion uptake greatly increases prognostication by 64Cu-DOTATATE PET/CT. Combining lesion uptake and total tumor volume, we derived a novel prognostic classification system for patients with NENs.
Keywords: 64Cu-DOTATATE PET; minimum SUVmean; neuroendocrine neoplasms; semiautomatic tumor delineation; total tumor volume.
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.
Figures



Similar articles
-
64Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms.J Nucl Med. 2020 Oct;61(10):1491-1497. doi: 10.2967/jnumed.119.240143. Epub 2020 Feb 28. J Nucl Med. 2020. PMID: 32111685 Free PMC article.
-
Prognostic Value of 18F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy.J Nucl Med. 2020 Nov;61(11):1560-1569. doi: 10.2967/jnumed.119.241414. Epub 2020 Mar 13. J Nucl Med. 2020. PMID: 32169914
-
Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE.J Nucl Med. 2021 Oct;62(10):1406-1414. doi: 10.2967/jnumed.120.256727. Epub 2021 Feb 12. J Nucl Med. 2021. PMID: 33579805 Free PMC article.
-
Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy.Eur Radiol. 2023 Oct;33(10):7089-7098. doi: 10.1007/s00330-023-09697-8. Epub 2023 May 6. Eur Radiol. 2023. PMID: 37148355 Review.
-
Copper Cu 64 Dotatate.2024 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2024 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 33497164 Free Books & Documents. Review.
Cited by
-
Prediction of 177Lu-DOTATATE Therapy Outcomes in Neuroendocrine Tumor Patients Using Semi-Automatic Tumor Delineation on 68Ga-DOTATATE PET/CT.Cancers (Basel). 2023 Dec 31;16(1):200. doi: 10.3390/cancers16010200. Cancers (Basel). 2023. PMID: 38201627 Free PMC article.
-
International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology.Eur J Nucl Med Mol Imaging. 2023 Oct;50(12):3513-3537. doi: 10.1007/s00259-023-06406-x. Epub 2023 Aug 25. Eur J Nucl Med Mol Imaging. 2023. PMID: 37624384 Free PMC article.
-
Applications of Artificial Intelligence and Radiomics in Molecular Hybrid Imaging and Theragnostics for Neuro-Endocrine Neoplasms (NENs).Life (Basel). 2023 Jul 28;13(8):1647. doi: 10.3390/life13081647. Life (Basel). 2023. PMID: 37629503 Free PMC article. Review.
-
Prognostic Value of Volume-Based Parameters Measured by SSTR PET/CT in Neuroendocrine Tumors: A Systematic Review and Meta-Analysis.Front Med (Lausanne). 2021 Nov 26;8:771912. doi: 10.3389/fmed.2021.771912. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34901087 Free PMC article.
-
Prospective Phase II Trial of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET/CT Imaging of Integrin αvβ3 for Prognostication in Patients with Neuroendocrine Neoplasms.J Nucl Med. 2023 Feb;64(2):252-259. doi: 10.2967/jnumed.122.264383. Epub 2022 Aug 18. J Nucl Med. 2023. PMID: 35981899 Free PMC article. Clinical Trial.
References
-
- WHO Classification of Tumours Editorial Board. Digestive System Tumours. 5th ed. International Agency for Research on Cancer; 2019:16–19.
-
- Couvelard A, Deschamps L, Ravaud P, et al. . Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors. Mod Pathol. 2009;22:273–281. - PubMed
-
- Miller HC, Drymousis P, Flora R, Goldin R, Spalding D, Frilling A. Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease. World J Surg. 2014;38:1353–1361. - PubMed
-
- Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol. 2011;35:853–860. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources